Ticker brief
UTHR UNITED THERAPEUTICS CORP
Consumer, Non-cyclical · Biotechnology
last close
$587.50
1 day
+0.5%
14 days
+7.0%
mkt cap
$23.6B
signals 14d
26
authors 14d
22
crowd 14d
+0.9σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 37% mid · 66 pctile own 1y | IV/HV 0.86× |
| Skew — 25Δ RR 30d | -0.010 53 pctile own 1y | balanced vs own range |
| OI alarm | quiet | last alarm 2026-05-07 (z=5.2) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-03 → 2026-10-15 · now +0.00 (−1 bearish … +1 bullish)
Who spoke22
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Quantumup1 | C | +0.10 | 3 | +0.05 |
| @PeloSwing | C | +1.05 | 2 | +0.47 |
| @OracleNYSE | C | +0.83 | 2 | -0.02 |
| @Tickeron | C | +1.53 | 1 | +0.55 |
| @Pharmdca | C | -3.41 | 1 | +0.00 |
| @BiopharmIQ | B | · | 1 | +0.20 |
| @Capitol_Forum | A | -0.51 | 1 | +0.20 |
| @DeepValuePlay | B | -2.26 | 1 | +0.10 |
| @joinautopilot | C | -0.83 | 1 | +0.15 |
| @tenet_research | C | -1.23 | 1 | -0.20 |
| @AlertsAndNews | C | -3.92 | 1 | +0.15 |
| @Sir_Kory | C | -2.14 | 1 | +0.10 |
| @SpecialSitsNews | B | -2.08 | 1 | +0.25 |
| @BankTheTrade | C | -0.03 | 1 | +0.20 |
| @IngJuanPa7 | B | +0.98 | 1 | -0.05 |
| @OpenOutcrier | C | · | 1 | -0.10 |
| @dangerousteee | C | -0.14 | 1 | -0.10 |
| @Biomaven | A | -0.63 | 1 | +0.30 |
| @Omnitrader69 | C | -2.17 | 1 | -0.45 |
| @FiercePharma | B | +0.46 | 1 | +0.35 |
| @nanalyzetweets | B | +5.59 | 1 | +0.20 |
| @Biotech2k1 | A | +1.11 | 1 | -0.20 |
Recent signals26of 26 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @Biotech2k1 | -0.20 | Argues INSM's TPIP is patent-distinct and could generate over $5B despite rivals' doubts. | +8.5% | tweet ↗ |
| 2026-10-15 | @nanalyzetweets | +0.20 | Reports a $381 million settlement ending six lawsuits while keeping LQDA's YUTREPIA on market. | +8.5% | tweet ↗ |
| 2026-10-14 | @FiercePharma | +0.35 | An analyst characterizes United Therapeutics' result against Liquidia as a clear-cut win. | +8.8% | tweet ↗ |
| 2026-10-14 | @Omnitrader69 | -0.45 | Criticizes UTHR for allegedly trying to prevent ILD-related revenue from escaping. | +8.8% | tweet ↗ |
| 2026-10-14 | @Biomaven | +0.30 | Says off-label LQDA use will be severely restricted, favoring UTHR while LQDA's next-generation drug remains in trials. | +8.8% | tweet ↗ |
| 2026-10-14 | @PeloSwing | +0.25 | Reports yesterday's large UTHR call purchase and current underlying price. | +8.8% | tweet ↗ |
| 2026-10-14 | @dangerousteee | -0.10 | Liquidia settled six disputes with United Therapeutics, clarifying continued access to Yutrepia. | +8.8% | tweet ↗ |
| 2026-10-14 | @OpenOutcrier | -0.10 | Liquidia and United Therapeutics settled all pending litigation, preserving YUTREPIA commercialization. | +8.8% | tweet ↗ |
| 2026-10-14 | @IngJuanPa7 | -0.05 | Liquidia settles a years-long drug dispute with United Therapeutics, sending LQDA nearly 40% higher. | +8.8% | tweet ↗ |
| 2026-10-14 | @BankTheTrade | +0.20 | The companies ended six lawsuits in a settlement keeping Yutrepia on the market. | +8.8% | tweet ↗ |
| 2026-10-14 | @SpecialSitsNews | +0.25 | Details a global settlement ending litigation while preserving LQDA's core product access. | +8.8% | tweet ↗ |
| 2026-10-14 | @Quantumup1 | +0.00 | Defends concern about how LQDA may finance obligations to UTHR. | +8.8% | tweet ↗ |
| 2026-10-14 | @Sir_Kory | +0.10 | Reports settlement of six lawsuits, payment terms, label changes and preliminary sales. | +8.8% | tweet ↗ |
| 2026-10-13 | @AlertsAndNews | +0.15 | Liquidia and United Therapeutics settled six lawsuits while preserving YUTREPIA commercialization. | +8.1% | tweet ↗ |
| 2026-10-13 | @Quantumup1 | +0.10 | Argues LQDA will likely need financing despite favorable settlement news. | +8.1% | tweet ↗ |
| 2026-10-13 | @Quantumup1 | +0.05 | Attributes LQDA's muted reaction to an expected capital raise to pay UTHR. | +8.1% | tweet ↗ |
| 2026-10-13 | @tenet_research | -0.20 | Liquidia settled six lawsuits with United Therapeutics for $380.7M and surged 40%. | +8.1% | tweet ↗ |
| 2026-10-09 | @joinautopilot | +0.15 | Lists same-day gains in six holdings associated with Jim Simons. | +7.0% | tweet ↗ |
| 2026-10-08 | @DeepValuePlay | +0.10 | Expresses doubt that UTHR agreed to royalties. | +10.3% | tweet ↗ |
| 2026-10-08 | @Capitol_Forum | +0.20 | Digest includes a patent loss, federal policy actions and a million-bed recall. | +10.3% | tweet ↗ |
| 2026-10-07 | @OracleNYSE | -0.20 | Reports revival of Liquidia's tortious-interference claim against United Therapeutics. | +7.8% | tweet ↗ |
| 2026-10-07 | @OracleNYSE | +0.15 | Court ruling upheld UTHR's antitrust win while reviving LQDA's contract case for trial. | +7.8% | tweet ↗ |
| 2026-10-05 | @BiopharmIQ | +0.20 | Weekly biotech roundup highlights patent, investment, clinical-data and analyst developments. | +9.5% | tweet ↗ |
| 2026-10-05 | @Pharmdca | +0.00 | Describes competing remedy proposals and timing for a pending regulatory binary affecting both firms. | +9.5% | tweet ↗ |
| 2026-10-05 | @PeloSwing | +0.70 | Reports $1.1M purchased in Nov 20 UTHR $560 calls. | +9.5% | tweet ↗ |
| 2026-10-03 | @Tickeron | +0.55 | A federal patent ruling hurt LQDA and benefited patent holder UTHR; analysts also cut LQDA ratings or targets. | +8.5% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.